Lead Product(s) : Tecarfarin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $5.1 million
Deal Type : Financing
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
Details : The net proceeds will be used in developing ATI-5923 (tecarfarin), a new vitamin K antagonist (VKA), prepare for our pivotal Phase 3 trial.
Brand Name : ATI-5923
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 24, 2024
Lead Product(s) : Tecarfarin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $5.1 million
Deal Type : Financing
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cytokinetics Starts CEDAR-HCM Trial for Pediatric Obstructive Hypertrophic Cardiomyopathy
Details : CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under clinical development for obstructive hypertrophic cardiomyopathy in pediatric population.
Brand Name : CK-3773274
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 08, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pentagalloyl Glucose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Norwest Venture Partners
Deal Size : $96.0 million
Deal Type : Series D Financing
Nectero Medical Announces Completion of $96M Series D Financing
Details : The net Proceeds will be utilized to accelerate the clinical advancement of the Nectero EAST (pentagalloyl glucose) for the treatment abdominal aortic aneurysms.
Brand Name : Nectero EAST
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 11, 2024
Lead Product(s) : Pentagalloyl Glucose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Norwest Venture Partners
Deal Size : $96.0 million
Deal Type : Series D Financing
Lead Product(s) : Pentagalloyl Glucose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nectero Medical Initiates Phase II/III Trial Of Nectero EAST® System
Details : The Nectero EAST System delivers pentagalloyl glucose locally into aneurysmal walls for treating small- to medium-sized abdominal aortic aneurysms in Phase 2/3.
Brand Name : Nectero EAST
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 18, 2024
Lead Product(s) : Pentagalloyl Glucose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tecarfarin,Warfarin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : The Sage Group
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Sage Group will assist Cadrenal in exploring strategic partnerships, co-development and licensing agreements for ATI-5923 (tecarfarin), a late-stage, novel, oral and reversible anticoagulant designed to prevent heart attacks, strok...
Brand Name : ATI-5923
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 12, 2023
Lead Product(s) : Tecarfarin,Warfarin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : The Sage Group
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : TOTUM•854
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TOTUM•854, a patented active substance based on a combination of plant extracts, is developed to reduce blood pressure in people with mild to moderate hypertension, by reducing angiotensin I-converting enzyme (ACE1) activity.
Brand Name : Totum-854
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 30, 2023
Lead Product(s) : TOTUM•854
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AV-101 is an investigational, proprietary dry powder inhaled formulation of the anti-proliferative drug imatinib. Developed specifically for PAH, AV-101 is designed for deliver